This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
KPI optimization is critical to improving the performance of your independent pharmacy. If you dont measure it, you cant improve itthis statement has never been truer for pharmacy owners. Key Performance Indicators (KPIs) are the benchmarks of success, providing insights into your pharmacys performance and guiding smarter decisions. Yet, many pharmacy owners overlook this critical aspect, focusing on day-to-day operations without a clear picture of their businesss health.
As glucagon-like peptide-1 (GLP-1) receptor agonists continue to surge in popularity, the U.S. Food and Drug Administration approved the second generic in this class of medications: liraglutide (Victoza). This approval follows the generic version of Byetta (another GLP-1) in November. Generic liraglutide is the first once-daily generic GLP-1 injectable approved to treat Type 2 diabetes in patients 10 and older, alongside diet and exercise.
The new year ushered in a final slate of updates to the federal rules for how hospitals have to disclose their prices, and experts are optimistic the changes will make the data more helpful in identifying less expensive providers. The updates are fairly straightforward. The government is requiring hospitals to include additional pieces of data to improve their consistency and make it easier to compare across hospitals.
The RNA therapeutics industry stands poised for a transformative 2025, driven by breakthroughs in technology, expanding clinical applications, and a rapidly growing pipeline of innovative therapies. Following the unprecedented speed and success of mRNA-based COVID-19 vaccine development, the field has experienced a surge in investment and research to unlock the powerful potential of RNA for other therapeutic applications.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The National Institute for Health and Care Excellence (NICE) has recommended the first drug for NHS use to prevent cisplatin-induced hearing loss ( ototoxicity ) in children and young people between the ages of one month and 17 years old.Pedmarqsi (anhydrous sodium thiosulfate) is indicated for these children who have localised, non-metastatic, solid tumours.
Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.
Jennifer Goldman, PharmD, CDCES, BC-ADM, discusses how putting glucagon kits in public areas and long-term care facilities can help patients with diabetes.
In this month's payer roundup, CVS faces antitrust questions from Congress as the company lays off more workers following a failed Medicaid bid in Kansas, Oscar Health CEO Mark Bertolini has a bold idea to remake health insurance and Johnson & Johnson is suing Express Scripts in a long-running lawsuit.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The group is concerned about understaffing, retention challenges and low pay. NYC H+H affiliates and the Doctors Council have been negotiating a new contract for 15 months.
The challenges facing oncology clinical trials are multifaceted, but there is a clear opportunity for pharmaceutical companies to rethink their approach to clinical research, and prioritise the patient from the beginning.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacists can educate patients on controlling risk factors and stay up-to-date on emerging therapies like SGLT2 inhibitors and finerenone that can slow disease progression.
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
HHS is backing away from a proposed rule that would've worked around an employer's religious objections to contraceptive coverage without cost sharing.
Benadryl (with the active ingredient diphenhydramine Hcl) is an allergy medication and over-the-counter antihistamine. It works as an histamine receptor antagonist against histamine receptors, blocking histamine from binding and preventing allergic reactions. It can treat hay fever, allergy symptoms, cold symptoms, and insomnia. People can take it as a capsule, tablet, orally dissolving film, or liquid.
Glucagon-like peptide-1 receptor agonists (GLP-1s) are drugs that act like the GLP-1 hormone that the human body should release naturally in the gastrointestinal tract after eating. GLP-1 performs many functions in the body, including triggering the release of insulin from the pancreas, improving insulin resistance, slowing down the emptying of the stomach, and increasing the feeling of satiety.
UnitedHealth Group and Amedisys have pushed back the closure date for their $3.3 billion merger as they fend off a federal challenge to the deal. | UnitedHealth Group and Amedisys have pushed back the closure date for their $3.3 billion merger as they fend off a federal challenge to the deal.
NeueHealth, the care management company formerly known as Bright Health, is set to be acquired by venture capital partner New Enterprise Associates later this month. | NeueHealth is getting bought out by an affiliate of New Enterprise Associates, making the company privately held.
Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin inflammation.
Although each of the product samples of phenibut contained the actual active ingredient, the exact amount of the active ingredient was inaccurate and, in one sample, found to be at a higher dose.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content